Abstract

Introduction: Cutaneous Squamous Cell Carcinoma (cSCC) is a prevalent skin malignancy, with recurrent cases posing significant challenges, particularly in elderly patients. Immune checkpoint inhibitors, such as anti-PD-1 antibodies, have shown promise in advanced cSCC.
Objective: To report the efficacy and tolerability of Sintilimab, an anti-PD-1 monoclonal antibody, in an elderly patient with recurrent cSCC post-radiotherapy.
Research method: A case study was conducted on an 88-year-old female with recurrent stage III cSCC at Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, Fujian, China. She received Sintilimab (200mg intravenously every 21 days) for three cycles, with clinical outcomes assessed via physical examination and imaging.
Result: Sintilimab achieved significant tumor shrinkage and pain relief with excellent tolerability. No significant adverse effects were observed. The patient died of COVID-19, unrelated to her cancer treatment.

Keywords:Cutaneous squamous cell carcinoma; Sintilimab; Immunotherapy; Radiotherapy; Elderly; Recurrence